Integral Diagnostics Management
Management criteria checks 1/4
Integral Diagnostics' CEO is Ian Kadish, appointed in May 2017, has a tenure of 7.58 years. total yearly compensation is A$1.24M, comprised of 66.3% salary and 33.7% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth A$1.71M. The average tenure of the management team and the board of directors is 0.8 years and 1.3 years respectively.
Key information
Ian Kadish
Chief executive officer
AU$1.2m
Total compensation
| CEO salary percentage | 66.3% |
| CEO tenure | 7.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
Feb 21
Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Nov 22Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Feb 20These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Dec 14Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
May 26Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Feb 28Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Feb 25Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
Oct 29Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Sep 13An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued
Jun 04Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?
May 14Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?
May 03We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt
Apr 16Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?
Mar 27Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?
Mar 17The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About
Mar 07Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend
Feb 25Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?
Feb 23Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?
Feb 13Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03
Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)
Jan 24Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?
Jan 14Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return
Jan 05Is Integral Diagnostics (ASX:IDX) A Risky Investment?
Dec 26At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?
Dec 17What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend
Dec 08Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture
Nov 29Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?
Nov 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$1m | AU$825k | -AU$61m |
| Mar 31 2024 | n/a | n/a | -AU$59m |
| Dec 31 2023 | n/a | n/a | -AU$58m |
| Sep 30 2023 | n/a | n/a | -AU$16m |
| Jun 30 2023 | AU$1m | AU$794k | AU$25m |
| Mar 31 2023 | n/a | n/a | AU$23m |
| Dec 31 2022 | n/a | n/a | AU$21m |
| Sep 30 2022 | n/a | n/a | AU$18m |
| Jun 30 2022 | n/a | AU$781k | AU$15m |
| Mar 31 2022 | n/a | n/a | AU$18m |
| Dec 31 2021 | n/a | n/a | AU$22m |
| Sep 30 2021 | n/a | n/a | AU$26m |
| Jun 30 2021 | AU$2m | AU$736k | AU$31m |
| Mar 31 2021 | n/a | n/a | AU$32m |
| Dec 31 2020 | n/a | n/a | AU$32m |
| Sep 30 2020 | n/a | n/a | AU$28m |
| Jun 30 2020 | AU$1m | AU$635k | AU$23m |
| Mar 31 2020 | n/a | n/a | AU$22m |
| Dec 31 2019 | n/a | n/a | AU$21m |
| Sep 30 2019 | n/a | n/a | AU$21m |
| Jun 30 2019 | AU$876k | AU$549k | AU$21m |
| Mar 31 2019 | n/a | n/a | AU$19m |
| Dec 31 2018 | n/a | n/a | AU$17m |
| Sep 30 2018 | n/a | n/a | AU$16m |
| Jun 30 2018 | AU$711k | AU$489k | AU$15m |
Compensation vs Market: Ian's total compensation ($USD773.43K) is about average for companies of similar size in the Australian market ($USD872.27K).
Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.
CEO
Ian Kadish (61 yo)
7.6yrs
Tenure
AU$1,243,752
Compensation
Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 7.6yrs | AU$1.24m | 0.25% A$ 1.7m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Information Officer | 5.3yrs | no data | no data | |
| Chief Integration Officer | no data | no data | no data | |
| Chief Medical Officer | no data | no data | no data | |
| Company Secretary | less than a year | no data | no data |
0.8yrs
Average Tenure
Experienced Management: IDX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | no data | AU$1.24m | 0.25% A$ 1.7m | |
| Independent Non-Executive Director | 7.2yrs | AU$140.53k | 0.013% A$ 90.4k | |
| Independent Non-Executive Director | 2.4yrs | AU$137.50k | 0.036% A$ 248.2k | |
| Independent Non-Executive Director | 1.3yrs | AU$111.22k | 0.015% A$ 102.2k | |
| Independent Non-Executive Chairman | 1.3yrs | AU$168.37k | 0.066% A$ 448.3k | |
| Independent Non-Executive Director | no data | no data | 0.0063% A$ 43.2k | |
| Independent Non-Executive Director | no data | no data | no data |
1.3yrs
Average Tenure
59yo
Average Age
Experienced Board: IDX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 09:58 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Integral Diagnostics Limited is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |